Micro-RNAs, the Cornerstones of the Future of Radiobiology in Head and Neck Cancers?
- PMID: 35200568
- PMCID: PMC8870960
- DOI: 10.3390/curroncol29020069
Micro-RNAs, the Cornerstones of the Future of Radiobiology in Head and Neck Cancers?
Abstract
Even though it is only the 6th most common malignancy at the modal level, head and neck cancers are distinguished by a considerable treatment failure rate, especially by locoregional recurrences, the intrinsic tumor radioresistance being one of the causes of this phenomenon. The efforts of radiobiological research of these cancers are oriented towards the identification of biomarkers associated with radioresistance and radiosensitivity in order to modulate the treatment so that the therapeutic benefit is maximum. Micro-RNAs (miRNAs, miRs), small single-stranded non-coding RNA molecules are currently being extensively evaluated as potential biomarkers in numerous diseases, including cancer. The evaluation of the potential of miRNAs to modulate or predict radiosensitivity or radioresistance, to anticipate the risk of recurrence and metastasis, and to differentiate different tumor subtypes is based on multiple mechanisms by which mRNAs control proliferation and apoptosis and interact with cell cycle phases or act as oncogenes with the potential to influence invasion promotion or tumor suppression. A refinement of radiosensitivity based on miRNAs with clinical and radiobiological application in head and neck cancers can lead to a personalization of radiotherapy. Thus, a miRNA signature can anticipate the risk of toxicity associated with chemoradiation, the possibility of obtaining locoregional control after treatment, and the recurrence and distant metastasis risk. The potential of miRNAs as an intrinsic predictor of sensitivity to chemotherapy may also guide the therapeutic decision toward choosing an escalation or de-escalation of concurrent or sequential systemic treatment. The choice of the irradiated dose, the fractional dose, the fractionation scheme, and the refining of the dose-volume constraints depending on the radiosensitivity of each tissue type estimated on a case-by-case basis by miRNAs profile are possible concepts for the future radiotherapy and radiobiology of head and neck cancers.
Keywords: chemotherapy; head and neck cancers; microRNAs; radiobiology; radioresistance; radiosensitivity.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients.Clin Cancer Res. 2015 Dec 15;21(24):5630-8. doi: 10.1158/1078-0432.CCR-15-0454. Epub 2015 Aug 11. Clin Cancer Res. 2015. PMID: 26265694
-
[MicroRNAs in Prediction of Response to Radiotherapy in Head and Neck Cancer Patients - Pilot Study].Klin Onkol. 2018 Spring;31(Supplementum1):137-139. Klin Onkol. 2018. PMID: 29808687 Czech.
-
[Radiosensitivity and/or radioresistance of head and neck cancers: Biological angle].Bull Cancer. 2016 Jan;103(1):41-7. doi: 10.1016/j.bulcan.2015.10.016. Epub 2015 Dec 17. Bull Cancer. 2016. PMID: 26702507 Review. French.
-
MicroRNAs Involvement in Radioresistance of Head and Neck Cancer.Dis Markers. 2017;2017:8245345. doi: 10.1155/2017/8245345. Epub 2017 Feb 23. Dis Markers. 2017. PMID: 28325958 Free PMC article. Review.
-
A radiosensitivity MiRNA signature validated by the TCGA database for head and neck squamous cell carcinomas.Oncotarget. 2015 Oct 27;6(33):34649-57. doi: 10.18632/oncotarget.5299. Oncotarget. 2015. PMID: 26452218 Free PMC article.
Cited by
-
Tumor-Suppressive and Oncogenic Roles of microRNA-149-5p in Human Cancers.Int J Mol Sci. 2022 Sep 16;23(18):10823. doi: 10.3390/ijms231810823. Int J Mol Sci. 2022. PMID: 36142734 Free PMC article. Review.
-
Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment.Front Pharmacol. 2023 May 3;14:1174330. doi: 10.3389/fphar.2023.1174330. eCollection 2023. Front Pharmacol. 2023. PMID: 37205904 Free PMC article. Review.
-
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers-Early Experiences from Romania and Literature Review.Diagnostics (Basel). 2023 Aug 8;13(16):2620. doi: 10.3390/diagnostics13162620. Diagnostics (Basel). 2023. PMID: 37627878 Free PMC article.
References
-
- Epidemiology and Risk Factors for Head and Neck Cancer, Global Cancer Observatory International Agency for Research on Cancer. World Health Organization. [(accessed on 6 June 2021)]. Available online: https://gco.iarc.fr/
-
- Brockstein B., Haraf D.J., Rademaker A.W., Kies M.S., Stenson K.M., Rosen F., Mittal B.B., Pelzer H., Fung B.B., Witt M.E., et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004;15:1179–1186. doi: 10.1093/annonc/mdh308. - DOI - PubMed
-
- Langendijk J.A., Doornaert P., Verdonck-de Leeuw I.M., Leemans C.R., Aaronson N.K., Slotman B.J. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J. Clin. Oncol. 2008;26:3770–3776. doi: 10.1200/JCO.2007.14.6647. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical